This workflow confirms and quantifies 31 drugs of abuse in oral fluid (including THC) in a 4.5‑minute LC run on the <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1149">Thermo Scientific Stellar mass spectrometer</a> using full scan + targeted MS2 (tMS2) with both HCD and CID fragmentation. With 1 µL injection and 0.1% formic acid in water/methanol mobile phases, the method supports ~13 samples/hour (up to ~320/day continuous operation) while maintaining confirmation performance via ion ratios.<blockquote><h5>Method at a glance</h5><ul><li>What matrix is tested? Oral fluid</li><li>How many drugs? 31 drugs of abuse (panel includes THC)</li><li>Run time? 4.5 minutes</li><li>Throughput? ~13 samples/hour → up to ~320 samples/day (24‑hour operation)</li><li>Injection volume? 1 µL</li><li>Mobile phases? 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B)</li><li>MS acquisition? Full scan + targeted MS2 (tMS2)</li><li>Fragmentation? Compound‑optimized HCD and CID in the same targeted list</li><li>Confirmation strategy? Ion ratios with ±20% tolerance (typical confirmatory approach)</li></ul></blockquote><h3>Why oral fluid—and why speed matters</h3>Oral fluid is attractive for clinical and forensic toxicology because collection is simple and the matrix aligns well with high‑volume workflows (workplace/occupational, roadside, and other settings). The challenge is building a method that’s simultaneously:<ul><li>Broad enough for today’s drug panels</li><li>Sensitive enough to reach required cutoffs</li><li>Fast enough to keep sample queues under control</li><li>Confirmation‑ready (consistent product ions and ion ratios)</li></ul>A 4.5‑minute method is a practical lever here: compress runtime, raise throughput, and still keep confirmation quality by optimizing MS/MS conditions per compound.<h3>The LC method</h3>A short, efficient separation is the foundation of the workflow:<ul><li>UHPLC system: <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/744">Thermo Scientific Vanquish Horizon UHPLC</a></li><li>Column: <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/424">Thermo Scientific Accucore Biphenyl</a>, 50 × 2.1 mm, 2.6 µm</li><li>Mobile phase A: 0.1% formic acid in water</li><li>Mobile phase B: 0.1% formic acid in methanol</li><li>Injection volume: 1 µL</li><li>Gradient runtime: 4.5 minutes</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_fd3f3e8ea4.jpg" alt="Thermo Fisher Scientific: 4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS: Figure 1: Thermo Scientific Vanquish Horizon UHPLC system." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_fd3f3e8ea4.jpg 120w," sizes="100vw" width="747" height="969"><h3>The MS method (Full scan + targeted MS2 with HCD + CID)</h3><h5>Acquisition approach</h5>This method uses a “two‑layer” strategy for quantitation + confirmation:<ol><li>Full scan (broad coverage, context, quantitative support)</li><li>Targeted MS2 (tMS2) (confirmation‑focused product ions, ion ratios)</li></ol><h5>The key differentiator: HCD and CID in one targeted list</h5>Instead of forcing every analyte into a single fragmentation style, the method uses both:<ul><li>HCD (beam‑type fragmentation)</li><li>CID (resonance‑type fragmentation)</li></ul><h5>Why that improves method development:</h5>Drugs of abuse span multiple chemistries. A single collision approach often works “okay” for most compounds—but one or two analytes can become persistent problems (weak qualifiers, unstable ion ratios, excess noise). Having both HCD and CID available in one method lets you optimize per compound and move faster.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_3_e4a95651a2.jpg" alt="Thermo Fisher Scientific: 4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS: Figure 2: Thermo Scientific Stellar mass spectrometer." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_3_e4a95651a2.jpg 245w," sizes="100vw" width="645" height="377"><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_5_88276eec6a.jpg" alt="Thermo Fisher Scientific: 4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS: Figure 3: Full scan &amp; targeted MS2 methods, HCD and collision energies used." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_5_88276eec6a.jpg 245w," sizes="100vw" width="768" height="279"><h3>Why CID + HCD flexibility improves confirmation</h3>In this workflow, HCD performed well for most compounds. But for buprenorphine, HCD produced one dominant product ion with additional low m/z noise and noticeable residual precursor. Using CID generated two high‑intensity product ions and delivered consistent ion ratios across the calibration range.When your confirmation hinges on stable ion ratios, the ability to switch fragmentation mode (not just collision energy) is a method‑development advantage—especially for “problem analytes.”<h3>Controllable ionization</h3>Oral fluid methods often deal with limited sample volume and matrix effects. This workflow pairs low injection volume with ionization control using the Thermo Scientific OptaMax Plus HESI source.<ul><li>The OptaMax Plus HESI source supports high probe temperature capability (up to 650 °C).</li><li>In this study, a vaporizer temperature of 500 °C was used to help achieve sensitivity and improve relative peak areas across drugs of abuse.</li></ul>Why this matters: If you’re injecting only 1 µL, ionization stability and efficiency can be the difference between “meets cutoff” and “misses at LOQ.”<h3>Sample preparation</h3>Oral fluid panels become more challenging when THC is included because most drugs of abuse are basic, while THC is largely neutral, and that can stress extraction chemistry.In this workflow, oral fluid calibrators and samples were extracted using a mixed‑mode approach designed to recover THC alongside other drugs:<ul><li>Calibrators prepared across eight levels (broad dynamic range)</li><li>Extraction performed using mixed‑mode chemistry tips (SCX/WAX) in a dispersive SPE‑style workflow</li><li>Steps automated on a liquid handling platform to support high‑throughput consistency</li><li>Samples dried and reconstituted prior to LC‑MS analysis</li><li>Only 1 µL injected per run</li></ul>Even if your lab uses different automation or consumables, the method structure (fast LC + full scan + targeted MS2 with dual fragmentation) transfers well.<blockquote><h5>Throughput math</h5><ul><li>4.5 minutes per injection → 60 / 4.5 = 13.3 injections/hour</li><li>That’s ~13 samples/hour in typical phrasing</li><li>Over 24 hours: 13.3 × 24 = ~320 samples/day (continuous operation)</li></ul>If you run a single shift, just scale accordingly (e.g., ~106/day for an 8‑hour shift, excluding QC and overhead).</blockquote><h3>Performance summary</h3><h5>Sensitivity and linearity</h5><ul><li>Linearity from LOQs as low as 0.25 ng/mL up to 1,000 ng/mL (panel-dependent)</li><li>For THC specifically: LOQ at 1 ng/mL, with a dynamic range extending to 1,000 ng/mL in this evaluation</li><li>Across the panel, LOQs were reported as lower than recommended confirmation cutoffs referenced in SAMHSA guidance and NSC Tier 1 cutoffs (study-specific outcome)</li></ul><h5>Confirmation via ion ratios</h5><ul><li>Ion ratios evaluated using ±20% tolerance (typical confirmatory acceptance framework)</li><li>The workflow produced consistent ion ratios across calibrator levels for the full panel in this evaluation</li></ul><h5>Case sample comparison (real-world relevance)</h5>When compared against a validated triple quadrupole method for case study samples, the Stellar MS workflow:<ul><li>Confirmed the positive hits observed by the reference method</li><li>Reported a few additional positives for select analytes, attributed to lower LOQs</li><li>Highlighted an operational efficiency point: 1 µL injection in this method versus 20 µL injection in the compared method</li></ul><h3>FAQ</h3><div><div><ol><li>How long does the LC‑MS run take for the 31‑drug oral fluid panel? 4.5 minutes per injection using a short UHPLC gradient. &nbsp;</li><li>How many drugs of abuse can Stellar MS detect in this workflow? 31 drugs of abuse, including THC, using full scan + targeted MS2. &nbsp;</li><li>What MS/MS approach is used? A combined strategy: full scan plus targeted MS2 (tMS2) for confirmation. &nbsp;</li><li>Why use both HCD and CID? Because some analytes fragment better—and produce more stable confirmation ions/ion ratios—under one mode versus the other. Using both increases flexibility and speeds method optimization. &nbsp;</li><li>What injection volume is used? 1 µL of extracted sample. &nbsp;</li><li>What mobile phases are used? 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). &nbsp;</li><li>How many samples can you run per day? At 4.5 minutes/injection, throughput is ~13 samples/hour or up to ~320/day with continuous operation (actual throughput depends on QC and scheduling).</li></ol></div></div><h3>What makes this workflow “easy” to develop on Stellar MS</h3>Here’s the short list of features that directly reduce method‑development friction:<ul><li>HCD or CID in one method → optimize per compound, not compromise</li><li>Fast MS2 acquisition speeds (up to 140 Hz for MS2) → more data points across narrow peaks</li><li>Fast polarity switching (true 5 ms) → supports mixed panels efficiently</li><li>Adaptive RT (real‑time retention time window adjustment) → helps reduce reinjections when retention times drift (e.g., column aging) and supports method transfer from longer to shorter gradients</li><li>OptaMax Plus HESI source control → supports sensitivity at low injection volumes</li></ul>If you’re building a fast oral fluid confirmation workflow—or updating an existing DOA panel—this 4.5‑minute method shows how Stellar MS can combine speed, confirmation-ready MS2, and fragmentation flexibility (HCD + CID) in a single targeted workflow. Reach out to learn how to adapt the targeted list, collision settings, and scheduling strategy to your lab’s cutoffs and throughput goals.<blockquote>Visit us on&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/showcase/72003132/admin/dashboard/">LinkedIn:</a>&nbsp;#MassSpectrometry #OralFluid #DrugsOfAbuse #MethodDevelopment #HighThroughput</blockquote>

4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS

<h2><a target="_blank" rel="noopener noreferrer" href="https://www.isc2026.org/">ISC 2026</a></h2>The <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/companies/314">International Symposium on Chromatography (ISC)</a> represents the oldest conference series on separation science. ISC symposia have been organised since 1956 in each even year. ISC is one of the premier meetings series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.<h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/events/644">35th International Symposium on Chromatography</a></h4>📆6. - 10. September 2026📍Prague, Czech Republic<h3>REGISTRATION</h3><blockquote>👉<a target="_blank" rel="noopener noreferrer" href="https://www.czech-in.org/cmPortalV15/Account/Login?ReturnUrl=%2FcmPortalV15%2FPortal%2FISC26%2Fnormal">Register HERE for the ISC 2026</a>Late Registration until 25 August 2026</blockquote><h3>INDUSTRY ACTIVITIES</h3><h4>Activity 1: Discussion Session: Industry &amp; Education</h4><ul><li>Monday, 7 September 2026 | 16:30-17:50</li><li>Place: Club A</li><li>Moderators: Tony Edge and Deirdre Cabooter&nbsp;</li></ul><h5>Concept:</h5>This discussion session will explore the relationship between education in separation science in academia and the expectations of industry, focusing on how universities and companies can better collaborate to prepare graduates for successful careers in analytical laboratories and R&amp;D environments. The goal of the session is to provide perspectives from both academia and industry on how education in chromatography and related separation techniques can evolve to better reflect current technological, methodological, and regulatory challenges.<h5>Discussion Topics:</h5><ul><li>Bridging academia and industry: how both sectors perceive current cooperation and where improvements are possible&nbsp;</li><li>Graduate preparedness: which skills and competencies are often missing when entering industrial roles, and in which areas graduates typically excel&nbsp;</li><li>Approaches to teaching separation science: how chromatography and related analytical techniques are taught across different universities and regions&nbsp;</li><li>Industry support for education: examples of collaboration such as internships, industrial placements, joint teaching activities, or access to instrumentation&nbsp;</li><li>Experiences with academia–industry partnerships: what models of cooperation have proven effective in practice&nbsp;</li><li>Future perspectives: how education in separation science should adapt to emerging trends such as automation, digitalization, sustainability, and regulatory requirements&nbsp;</li></ul><h5>Format:</h5>Moderated panel discussion with short introductory remarks from invited speakers representing both academia and industry, followed by an interactive discussion with the audience.<h5>Panelists:</h5><ul><li>Shimadzu&nbsp;</li><li>Novartis&nbsp;</li><li>Jelle De Vos, RIC Group&nbsp;</li><li>Davy Guillarme, University of Geneva&nbsp;</li><li>Caterina Temporini, University of Pavia&nbsp;</li></ul><h4>Activity 2: Career Presentation&nbsp;</h4><ul><li>Monday, 7 September 2026 | 18:00-19:00</li><li>Place: Club A</li><li>Moderators: Adrian Clarke and Martina Catani</li></ul><h5>Concept:</h5>This session will provide an overview of career opportunities in separation science across industry, highlighting the wide range of professional pathways available to graduates and experienced scientists working in chromatography and related analytical disciplines.Participating companies will introduce their organizations, present typical roles involving separation techniques, and share insights into the skills and competencies they seek in candidates. The session is intended to support students, early-career researchers, and experienced professionals interested in exploring career options in industry sectors.<h5>Discussion Topics:&nbsp;</h5><ul><li>Overview of career paths involving chromatography and separation science&nbsp;</li><li>Entry-level opportunities for graduates and PhD holders&nbsp;</li><li>Positions for experienced scientists and technical specialists&nbsp;</li><li>Roles in R&amp;D, analytical development, quality control, regulatory science, application support, and instrument development&nbsp;</li><li>Skills and competencies valued by employers in separation science&nbsp;</li><li>Internships, graduate programs, and early-career development opportunities&nbsp;</li><li>Mobility between academia and industry&nbsp;</li></ul><h5>Format:</h5>Short presentation providing:<ul><li>overview of different carrier paths&nbsp;</li><li>introduction to the company and its activities related to separation science&nbsp;</li><li>examples of typical roles and career progression paths&nbsp;</li><li>information about current or expected hiring needs&nbsp;</li><li>advice for candidates interested in pursuing careers in industry&nbsp;</li><li>the session should include time for informal discussion, allowing participants to interact with company representatives and learn more about specific opportunities.&nbsp;</li></ul><h4>Activity 3: Job Fair</h4><ul><li>Monday, 7 September and Tuesday, 8 September 2026 | 12:30-14:00</li><li>Place: Club A</li><li>Main organizer: Adrian Clarke</li></ul><h5>Concept:</h5>The ISC 2026 Job Fair provides a structured opportunity for direct interaction between companies active in separation science and conference participants seeking career opportunities. The session is designed to facilitate efficient, focused conversations between employers and candidates interested in positions related to chromatography and analytical science.Participating candidates will submit their CV in advance allowing companies to review profiles prior to the event and identify potential matches based on expertise, experience, and career interests.<h5>Format:</h5>The Job Fair will follow a structured rotation format:<ul><li>Each participating company will be assigned a dedicated table&nbsp;</li><li>One company representative will meet candidates individually&nbsp;</li><li>Each candidate will have 5 minutes per meeting to introduce their background and interests&nbsp;</li><li>Participants will rotate between companies at timed intervals&nbsp;</li><li>Session timing will be managed by the organizer, with a signal indicating when to move to the next meeting&nbsp;</li></ul><h5>Candidates:</h5>Participants interested in joining the Job Fair are asked to:<ul><li>submit their CV before August 23rd &nbsp;</li><li>indicate areas of expertise and career interests&nbsp;</li><li>specify whether they are seeking internships, entry-level roles, or experienced positions&nbsp;</li><li>specify if you cannot be available on a certain day e.g. owing to poster presentation&nbsp;</li><li>send these materials to: <a href="mailto:careers@isc2026.org">careers@isc2026.org</a>&nbsp;</li></ul><h5>Companies:</h5>Confirmed participating companies to date include:<ul><li>Novartis&nbsp;</li><li>RIC Group&nbsp;</li><li>Shimadzu&nbsp;</li><li>further companies to be added&nbsp;</li></ul>Potential employers please register your interest to <a href="mailto:careers@isc2026.org">careers@isc2026.org</a> to participate in the speed-dating (first come first served basis).“Jobs position” board will be available in the Careers fair in the foyer in the symposium venue and attendees can visit the company booths in the exhibition hall or discuss with recruiting companies during the conference.<blockquote>Recruiters please send an email with your open positions to <a href="careers@isc2026.org">careers@isc2026.org</a> by the 23rd August and bring the job adverts to post on the jobs board (there will also be the possibility to upload the open positions to the Symposium app).</blockquote><h4>Activity 4: Discussion Session: Artificial Intelligence in Separation Science: From Concept to Practice</h4><ul><li>Tuesday, 8 September 2026 | 16:30-18:00</li><li>Place: Club A</li><li>Moderators: Bob Pirok</li></ul><h5>Concept:</h5>Artificial intelligence (AI) and data-driven approaches are increasingly influencing analytical chemistry, offering new possibilities for method development, data interpretation, process optimization, and decision support. This discussion session will explore how AI is currently being applied in separation science, with a particular focus on practical implementation in industry environments.The session aims to provide a realistic overview of the current state of AI adoption, highlighting both successful applications and remaining challenges. Contributions from industry and academia will help clarify where AI already delivers value, where expectations may exceed current capabilities, and what developments are needed to enable broader implementation.<h5>Discussion Topics:&nbsp;</h5><ul><li>Current applications of AI and machine learning in separation science&nbsp;</li><li>Use of AI in chromatographic method development and optimization&nbsp;</li><li>Data analysis, peak detection, and automated interpretation of complex datasets&nbsp;</li><li>AI-supported troubleshooting and predictive maintenance of analytical instruments&nbsp;</li><li>Integration of AI into regulated environments (e.g., pharmaceutical industry)&nbsp;</li><li>Data requirements, data quality, and standardization challenges&nbsp;</li><li>Comparison between academic developments and real-world industrial implementation&nbsp;</li><li>Barriers to adoption, including regulatory considerations, validation requirements, and transparency of models&nbsp;</li><li>Future outlook: digital laboratories, autonomous method development, and AI-assisted decision-making in analytical workflows&nbsp;</li></ul><h5>Format:</h5>Moderated panel discussion with short introductory remarks from invited speakers representing both academia and industry, followed by an interactive discussion with the audience.<h4>Activity 5: Discussion Session: Sustainability in Separation Science</h4><ul><li>Wednesday, 9 September 2026 | 16:30-18:00</li><li>Place: Club A</li><li>Moderators: Gertrud Morlock</li></ul><h5>Concept:</h5>Sustainability has become an increasingly important priority in analytical science, driving the development of greener methods, reduced solvent consumption, improved energy efficiency, and more responsible laboratory practices. While academic research frequently proposes innovative sustainable approaches, their implementation in industry is often influenced by additional considerations such as robustness, regulatory compliance, cost efficiency, scalability, and long-term reliability.This discussion session aims to explore how sustainability principles are applied in real industrial environments and how collaboration between academia and industry can help translate promising research concepts into practical, validated solutions.By bringing together perspectives from both sectors, the session will highlight opportunities to better align research priorities with industrial needs and identify realistic pathways toward more sustainable separation workflows.<h5>Discussion Topics:&nbsp;</h5><ul><li>Reduction of solvent consumption and the transition to more environmentally friendly mobile phases&nbsp;</li><li>Miniaturized and more efficient separation and extraction techniques&nbsp;</li><li>Energy consumption and efficiency of laboratory processes and analytical instrumentation&nbsp;</li><li>Lifecycle considerations for columns, consumables, and laboratory waste&nbsp;</li><li>Metrics and approaches for measuring and evaluating the “greenness” of analytical methods&nbsp;</li><li>Regulatory constraints and requirements that may limit the implementation of greener analytical workflows&nbsp;</li></ul><h5>Format:</h5>Moderated panel discussion with short introductory contributions from invited speakers representing industry, academia, and technology providers, followed by interactive discussion with the audience.<h5>Panelists:</h5><ul><li>Sébastien Rolle, Shimadzu&nbsp;</li><li>Ken Cook, Thermo Fisher Scientific&nbsp;</li><li>Andreas Otto, Agilent&nbsp;</li><li>Janusz Pawliszyn, University of Waterloo&nbsp;</li><li>Giorgia Purcaro, University of Liège&nbsp;</li></ul>

Industry program at ISC 2026

We are delighted to invite food scientists from academia and industry, representatives of (inter)national agencies, control authorities, governmental and commercial laboratories to attend <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/events/928">RAFA 2026</a> (12th Symposium on Recent Advances in Food Analysis), that takes place 3–6 November 2026 in Prague..<blockquote>👉<a target="_blank" rel="noopener noreferrer" href="https://rafa.easyevent.eu/tickets/">SUBMIT ABSTRACT</a> FOR POSTER PRESENTATION by August 31, 2026Do not miss the opportunity to present your latest results at RAFA 2026.</blockquote><h5>Next deadlines:</h5><ul><li>August 31, 2026: 2nd window – &nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/sponsors_exhibitors_media_partners_info.html">Application for participation as a Sponsor or Exhibitor</a></li><li>September 30, 2026:&nbsp;<ul><li><a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/registration.html">Registration at the regular rate</a></li><li>Abstract submission – Last minute posters (May not appear in the RAFA 2026 program)</li></ul></li></ul>Since its first edition in 2003, RAFA has grown into a prestigious international event, typically welcoming up to 850 participants from more than 60 countries worldwide, with the support of more than 50 sponsors, exhibitors, media and supporting partners.RAFA 2026 will provide an overview of contemporary trends in the ANALYTICAL &amp; BIOANALYTICAL STRATEGIES IN FOOD QUALITY AND SAFETY CONTROL and discuss the CHALLENGES AND NOVEL APPROACHES IN FOOD AND NATURAL PRODUCTS ANALYSIS.View the <a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/invited_speakers.html">list of distinguished speakers</a> who have accepted our invitation to RAFA 2026 and will present current hot topics and future perspectives in food analysis!<blockquote>👉More details on the <a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/scientific_programme.html">RAFA 2026 preliminary program</a> can be found HERE.👉OUR <a target="_blank" rel="noopener noreferrer" href="https://www.rafa2026.eu/about_sponsors_exhibitors_partners.html">SPONSORS, EXHIBITORS, MEDIA and SUPPORTING PARTNERS</a></blockquote>You are kindly invited to join and contribute to our exciting scientific program and unforgettable social events!We look forward to meeting you again in Prague!<ul><li>Prof. Jana Pulkrabova &amp; Dr. Stefan van Leeuwen, Symposium Chairs</li><li>Prof. Michele Suman, Symposium Co-chair</li><li>Prof. Jana Hajslova &amp; Prof. Michel Nielen, Symposium Honorary Chairs</li></ul>

RAFA 2026 - Deadline for Abstract Submission for poster presentation is coming

Article

Product

Events

Application

Food

Video

RAFA provides an overview of contemporary trends in ANALYTICAL & BIOANALYTICAL STRATEGIES IN FOOD QUALITY AND SAFETY CONTROL and discusses CHALLENGES / NOVEL APPROACHES IN FOOD AND NATURAL PRODUCTS ANALYSIS.

Recent Advances in Food Analysis (RAFA)

A unique company dedicated to serving science helping our customers drive productivity and accelerate results. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Thermo Fisher Scientific

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

L-Carnitine analysis

Targeted HPLC analysis of L-carnitine in tablets, capsules, liquid samples, and raw API powders, confirming identity and determining content.

The L-Carnitine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of L-carnitine in oral dosage forms, liquid samples, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule, as well as liquid samples, with results reported in mg/ml. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About L-Carnitine</h4>L-carnitine is a naturally occurring compound involved in mitochondrial fatty-acid metabolism. Its primary biological role is to transport long-chain fatty acids across the inner mitochondrial membrane, enabling their subsequent beta-oxidation and use as a source of cellular energy.In the human body, L-carnitine is obtained from dietary sources and can also be synthesised endogenously from the amino acids lysine and methionine. It is concentrated particularly in tissues with high energy demands, such as skeletal and cardiac muscle, and is also used therapeutically in the management of primary and secondary carnitine deficiencies.<h4>Key Features</h4><ul><li>Targeted identification and quantification of L-carnitine</li><li>Suitable for tablets, capsules, liquid samples, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for liquid samples reported in mg/ml</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum liquid sample amount of 0.5–1 ml</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: L-Carnitine</li><li>CAS number: 541-15-1</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for liquid samples: mg/ml</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for liquid samples: 0.5–1 ml</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for L-carnitine. It does not automatically screen the sample for related carnitine derivatives, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>Purity reporting in % (m/m) is available as an alternative result format.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Lipo-C (L-Carnitine content, L-Arginine Content, B12 Content, Total Solids)

Lipo-C analysis determines L-carnitine, L-arginine, vitamin B12, and total solids content, with target compounds analysed by HPLC.

The Lipo-C Analysis is a targeted laboratory test designed to determine the content of L-carnitine, L-arginine, and vitamin B12, together with the total solids content of a Lipo-C sample.The target compounds are analysed by HPLC, with results reported in mg/ml. Total solids provide an additional measure of the overall amount of solid material present in the sample, helping assess the composition of the formulation beyond the individual quantified compounds.<h4>About the Analyzed Compounds</h4>L-carnitine is involved in mitochondrial fatty-acid metabolism and facilitates the transport of long-chain fatty acids into mitochondria for beta-oxidation. L-arginine is an amino acid involved in several metabolic pathways and serves as a precursor for nitric oxide synthesis.Vitamin B12 (cobalamin) is an essential micronutrient that functions as a cofactor for enzymes involved in important metabolic reactions and DNA synthesis.Total solids represent the overall solid material present in a sample, including dissolved and suspended material. This measurement complements the targeted determination of L-carnitine, L-arginine, and vitamin B12.<h4>Key Features</h4><ul><li>Targeted determination of L-carnitine, L-arginine, and vitamin B12</li><li>Total solids determination included</li><li>Analysis of target compounds by HPLC</li><li>Results reported in mg/ml</li><li>Suitable for Lipo-C liquid samples</li><li>Minimum sample amount of one whole unopened vial</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: L-Carnitine, L-Arginine, Vitamin B12</li><li>Additional determination: Total Solids</li><li>Testing method: HPLC</li><li>Result format: mg/ml</li><li>Minimum sample amount: One whole unopened vial</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically designed to determine L-carnitine, L-arginine, vitamin B12, and total solids in a Lipo-C sample.</li><li>The analysis does not automatically screen the sample for other active compounds, ingredients, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NAD+ analysis

Targeted HPLC analysis of NAD+ in tablets, capsules, and raw API powders, confirming compound identity and determining its amount.

The NAD+ Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of NAD+ in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). NAD+ is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About NAD+</h4>NAD+ (nicotinamide adenine dinucleotide) is the oxidized form of an essential cellular coenzyme involved in redox reactions and energy metabolism. It accepts electrons during metabolic reactions and is converted to its reduced form, NADH, which participates in cellular energy production.NAD+ is present throughout cellular metabolism and plays an important role in maintaining the balance between oxidation and reduction reactions required for normal cellular function.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NAD+</li><li>Suitable for tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: NAD+</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: m/m purity in % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NAD+ is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NAD+. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>The stated detection limit cutoff is less than 1/20 of the usual dosage per vial.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NMN (Nikotinamid mononukleotid) analysis

Targeted HPLC analysis of NMN in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The NMN Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of nicotinamide mononucleotide (NMN) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About NMN</h4>Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and an intermediate in the biosynthesis of nicotinamide adenine dinucleotide (<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2546">NAD+</a>). NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs).NAD+ is an essential cellular coenzyme involved in energy metabolism, redox reactions, and numerous enzymatic processes. NMN has therefore been studied as an NAD+ precursor in both preclinical and clinical research.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NMN</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Nicotinamide mononucleotide</li><li>Other name: NMN</li><li>CAS number: 1094-61-7</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NMN is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NMN. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Sibutramine analysis

Targeted HPLC analysis of sibutramine in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Sibutramine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sibutramine in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Sibutramine</h4>Sibutramine is a serotonin-noradrenaline reuptake inhibitor (SNRI) that was formerly used as a weight-management medicine. By inhibiting the reuptake of serotonin and noradrenaline, it affects neurotransmitter signalling involved in appetite and satiety.Sibutramine-containing medicines were suspended in the European Union and withdrawn from the U.S. market after clinical data showed an increased risk of serious cardiovascular events, including heart attack and stroke.<h4>Key Features</h4><ul><li>Targeted identification and quantification of sibutramine</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Sibutramine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 4 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for sibutramine. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of sibutramine required for evaluation is 4 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li><li>Laboratory confirmation of sibutramine content should not be interpreted as confirmation that a product is safe for human use.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

SLU-PP-332 analysis

Targeted HPLC analysis of SLU-PP-332 in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The SLU-PP-332 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of SLU-PP-332 in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised vials, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). SLU-PP-332 is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About SLU-PP-332</h4>SLU-PP-332 is a synthetic research compound that acts as an agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. These nuclear receptors regulate genes involved in mitochondrial metabolism, oxidative phosphorylation, and fatty-acid oxidation.SLU-PP-332 has been investigated primarily in preclinical studies. In mouse models, activation of ERR signalling by SLU-PP-332 has been associated with increased oxidative skeletal muscle fibres, improved exercise endurance, increased energy expenditure, and enhanced fatty-acid oxidation.<h4>Key Features</h4><ul><li>Targeted identification and quantification of SLU-PP-332</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: SLU-PP-332</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised vials: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised vials: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>SLU-PP-332 is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For lyophilised SLU-PP-332 samples, the standard testing procedure uses water (H₂O) as the solvent. However, SLU-PP-332 is poorly soluble in water, and insoluble material may therefore be filtered out before analysis. Only dissolved material can be analysed.</li><li>DMSO can be selected as an alternative solvent because it dissolves SLU-PP-332 more effectively. However, samples dissolved in DMSO are not suitable for injection or human use. To use DMSO for the analysis, select the DMSO solvent option from the additional services.</li><li>This analysis is specifically intended for SLU-PP-332. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Solvent: DMSO</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T3 analysis

Targeted HPLC analysis of T3 (liothyronine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T3 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T3 (liothyronine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T3</h4>T3, or triiodothyronine, is a naturally occurring thyroid hormone involved in the regulation of metabolism, growth, and energy utilisation. Liothyronine is the synthetic form of T3 used in pharmaceutical preparations.Liothyronine sodium is used clinically as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism. Cytomel is one of the established trade names for liothyronine sodium.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T3</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T3</li><li>Other names: Cytomel, Tiromel, liothyronine sodium</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T3. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T3 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T4 analysis

Targeted HPLC analysis of T4 (thyroxine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T4 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T4 (thyroxine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in micrograms per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T4</h4>T4, or thyroxine, is the major thyroid hormone produced and secreted by the thyroid gland. It plays an important role in the regulation of metabolism, growth, development, and energy utilisation. Much of circulating T4 is converted in peripheral tissues to the more biologically active thyroid hormone <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2550">T3</a>.Levothyroxine is the synthetic form of T4 and is widely used as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T4</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mcg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T4</li><li>Other name: Thyroxine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mcg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T4. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T4 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Tesofensine analysis

Targeted HPLC analysis of tesofensine in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The Tesofensine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of tesofensine in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised samples, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). Tesofensine is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About Tesofensine</h4>Tesofensine is a centrally acting monoamine reuptake inhibitor that inhibits the reuptake of serotonin, noradrenaline, and dopamine. Its effects on these neurotransmitter systems have been investigated primarily in relation to appetite regulation and body weight.<h4>Key Features</h4><ul><li>Targeted identification and quantification of tesofensine</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Tesofensine</li><li>CAS number: 195875-84-4</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised samples: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Tesofensine is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for tesofensine. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>For raw API powders, at least 30 mg should be supplied in a sealed glass vial to minimise moisture absorption.</li><li>Purity reporting in % (m/m) is available for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Yohimbine Analysis

Targeted HPLC analysis of yohimbine in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Yohimbine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of yohimbine in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Yohimbine</h4>Yohimbine is a naturally occurring indole alkaloid that acts primarily as an antagonist of alpha-2 adrenergic receptors. Blocking these receptors can increase noradrenergic activity and influence sympathetic nervous system signalling.Yohimbine has historically been investigated and used in connection with erectile dysfunction, although its clinical effects have varied across studies and newer therapeutic options have largely replaced it for this indication.<h4>Key Features</h4><ul><li>Targeted identification and quantification of yohimbine</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Yohimbine</li><li>Other name: Yohi</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for yohimbine. It does not automatically screen the sample for related alkaloids, other active compounds, contaminants, or undeclared substances.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Products focused on Laboratory analysis - page 2

Related content

4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS

RAFA 2026 - Deadline for Abstract Submission for poster presentation is coming

Industry program at ISC 2026